FDA Clears Registrational C-CAR168 Study in Lupus Nephritis
FDA cleared AbelZeta to initiate a registrational Phase II study of C-CAR168 in refractory lupus nephritis. The autologous CAR-T product targets both CD20 and BCMA, seeking deeper depletion of B-lineage and plasma-cell compartments. Clearance…
